BEXLUTRY

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
BEXLUTRY
Generic name
LUTETIUM LU 177 DOTATATE
Manufacturer
Curium US LLC
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
d7642094-9ec6-4927-8582-bbe60e5e74cc
SPL ID
5ebf07f8-62f6-fd90-e063-6294a90ac739
Version
3
Effective date
2026-10-26
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:20:39
Harmonized routes table
Harmonized routes
INTRAVENOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Risk From Radiation Exposure : Minimize radiation exposure during and after treatment with BEXLUTRY consistent with institutional good radiation safety practices and patient management procedures. ( 2.1 , 5.1 ) Myelosuppression : Monitor blood cell counts. Withhold dose, reduce dose, or permanently discontinue based on the severity. ( 2.4 , 5.2 ) Secondary Myelodysplastic Syndrome (MDS) and Leukemia : Median time to onset: MDS is 29 months; acute leukemia is 55 months. ( 5.3 ) Renal Toxicity : Advise patients to hydrate and to urinate frequently before, on the day of and the day after administration of BEXLUTRY. Monitor serum creatinine and calculated creatinine clearance. Withhold dose, reduce dose, or permanently discontinue based on the severity. ( 2.3 , 2.4 , 5.4 ) Hepatotoxicity : Monitor transaminases, bilirubin, serum albumin and INR. ( 2.4 , 5.5 ) Hypersensitivity Reactions : Monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis. Permanently discontinue BEXLUTRY based on severity. ( 2.3 , 2.4 , 5.6 ) Neuroendocrine Hormonal Crisis : Monitor for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms. ( 5.7 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise females and males of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.8 , 8.1 , 8.3 ) Risk of Infertility : BEXLUTRY may cause infertility. ( 5.9 , 8.3 ) 5.1 Risk f rom Radiation Exposure BEXLUTRY contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. These risks of radiation associated with the use of BEXLUTRY are greater in pediatric patients than in adults [ see Use in Specific Populations ( 8.4 ) ]. Radiation can be detected in the urine for up to 30 days following BEXLUTRY administration. Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with BEXLUTRY consistent with institutional good radiation safety practices, patient management procedures, Nuclear Regulatory Commission patient-release guidance, and instructions to the patient for follow-up radiation protection at home [see Dosage and Administration ( 2.1 ) , Clinical Pharmacology ( 12.3 ) ] . 5.2 Myelosuppression In NETTER-1, myelosuppression occurred more frequently in patients receiving lutetium Lu 177 dotatate injection with long-acting octreotide compared to patients receiving high-dose long-acting octreotide (all Grades/Grade 3 or 4): anemia (81%/0) versus (54%/1%); thrombocytopenia (53%/1%) versus (17%/0); and neutropenia (26%/3%) versus (11%/0). In NETTER-1, platelet nadir occurred at a median of 5.1 months following the first dose. Of the 59 patients who developed thrombocytopenia, 68% had platelet recovery to baseline or normal levels. The median time to platelet recovery was 2 months. Fifteen of the nineteen patients in whom platelet recovery was not documented had post-nadir platelet counts. Among these 15 patients, 5 improved to Grade 1, 9 to Grade 2, and 1 to Grade 3. Monitor blood cell counts. Withhold dose, reduce dose, or permanently discontinue BEXLUTRY based on the severity of myelosuppression [see Dosage and Administration ( 2.4 ) ]. 5.3 Secondary Myelodysplastic Syndrome and Leukemia In NETTER-1, with a median follow-up time of 76 months in the main study, myelodysplastic syndrome (MDS) was reported in 2.3% of patients receiving lutetium Lu 177 dotatate injection with long-acting octreotide compared to no patients receiving high-dose long-acting octreotide. In ERASMUS, 16 patients (2.0%) developed MDS and 4 (0.5%) developed acute leukemia. The median time to onset was 29 months (9 to 45 months) for MDS and 55 months (32 to 125 months) for acute leukemia. 5.4 Renal Toxicity In ERASMUS, 8 patients (< 1%) developed renal failure 3 to 36 months following lutetium Lu 177 dotatate injection. Two of these patients had underlying renal impairment or risk factors for renal failure (e.g., diabetes or hypertension) and required dialysis. Administer the recommended amino acid solution before, during and after BEXLUTRY [see Dosage and Administration ( 2.3 ) ] to decrease the reabsorption of BEXLUTRY through the proximal tubules and decrease the radiation dose to the kidneys. Advise patients to hydrate and to urinate frequently before, on the day of, and the day after administration of BEXLUTRY. Monitor serum creatinine and calculated creatinine clearance. Withhold dose, reduce dose, or permanently discontinue BEXLUTRY based on the severity of renal toxicity [see Dosage and Administration ( 2.4 ) ]. Patients with baseline renal impairment may be at increased risk of toxicity due to increased radiation exposure [see Use in Specific Populations ( 8.6 )]. 5.5 Hepatotoxicity In ERASMUS, 2 patients (< 1%) were reported to have hepatic tumor hemorrhage, edema, or necrosis, with one patient experiencing intrahepatic congestion and cholestasis. Patients with hepatic metastasis may be at increased risk of hepatotoxicity due to radiation exposure. Monitor transaminases, bilirubin, serum albumin, and international normalized ratio (INR) during treatment. Withhold dose, reduce dose, or permanently discontinue BEXLUTRY based on the severity of hepatotoxicity [see Dosage and Administration ( 2.4 ) ]. 5.6 Hypersensitivity Reactions Hypersensitivity reactions, including angioedema, occurred in patients treated with lutetium Lu 177 dotatate injection [see Adverse Reactions ( 6.2 )]. Monitor patients closely for signs and symptoms of hypersensitivity reactions, including anaphylaxis, during and following BEXLUTRY administration for a minimum of 2 hours in a setting where cardiopulmonary resuscitation medication and equipment are available. Discontinue the infusion upon the first observation of any signs or symptoms consistent with a severe hypersensitivity reaction and initiate appropriate therapy. Premedicate patients with a history of Grade 1 or 2 hypersensitivity reactions to lutetium Lu 177 dotatate injection before subsequent doses [see Dosage and Administration ( 2.3 ) ]. Permanently discontinue BEXLUTRY in patients who experience Grade 3 or 4 hypersensitivity reactions [see Dosage and Administration ( 2.4 ) ]. 5.7 Neuroendocrine Hormonal Crisis Neuroendocrine hormonal crises, manifesting with flushing, diarrhea, bronchospasm and hypotension, occurred in < 1% of patients in ERASMUS and typically occurred during or within 24 hours following the initial lutetium Lu 177 dotatate injection dose. Two (< 1%) patients were reported to have hypercalcemia. Monitor patients for flushing, diarrhea, hypotension, bronchoconstriction or other signs and symptoms of tumor-related hormonal release. Administer intravenous somatostatin analogs, fluids, corticosteroids, and electrolytes as indicated. 5.8 Embryo-Fetal Toxicity Based on its mechanism of action, lutetium Lu 177 dotatate injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data on lutetium Lu 177 dotatate injection use in pregnant women. No animal studies using lutetium Lu 177 dotatate have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, radioactive emissions, including those from BEXLUTRY can cause fetal harm. Verify pregnancy status of females of reproductive potential prior to initiating BEXLUTRY [see Dosage and Administration ( 2.1 ) ]. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BEXLUTRY and for 7 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BEXLUTRY and for 4 months after the last dose [see Use in Specific Populations ( 8.1 , 8.3 )] . 5.9 Risk of Infertility BEXLUTRY may cause infertility in males and females. The recommended cumulative dose of 29.6 GBq of lutetium Lu 177 dotatate injection results in a radiation absorbed dose to the testes and ovaries within the range where temporary or permanent infertility can be expected following external beam radiotherapy [see Dosage and Administration ( 2.6 ) , Use in Specific Populations ( 8.3 ) ] .

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions ( 5.2 ) ] Secondary Myelodysplastic Syndrome and Leukemia [see Warnings and Precautions ( 5.3 )] Renal Toxicity [see Warnings and Precautions ( 5.4 ) ] Hepatotoxicity [see Warnings and Precautions ( 5.5 ) ] Hypersensitivity Reactions [see Warnings and Precautions ( 5.6 ) ] Neuroendocrine Hormonal Crisis [see Warnings and Precautions ( 5.7 ) ] Most common Grade 3-4 adverse reactions (≥ 4% with a higher incidence in lutetium Lu 177 dotatate injection arm) are lymphopenia, increased GGT, vomiting, nausea, increased AST, increased ALT, hyperglycemia and hypokalemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact CURIUM US LLC at 1-866-789-2211 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data in WARNINGS AND PRECAUTIONS reflect exposure to lutetium Lu 177 dotatate injection in 111 patients with advanced, progressive midgut neuroendocrine tumors (NETTER-1). Safety data in WARNINGS AND PRECAUTIONS were also obtained in an additional 22 patients in a non-randomized pharmacokinetic sub-study of NETTER-1 and in a subset of patients (811 of 1214) with advanced somatostatin receptor-positive tumors enrolled in ERASMUS [see Warnings and Precautions ( 5 ) ]. Adult Population NETTER-1 The safety data of lutetium Lu 177 dotatate injection with octreotide was evaluated in NETTER-1 [see Clinical Studies ( 14.1 ) ]. Patients with progressive, somatostatin receptor-positive midgut carcinoid tumors received lutetium Lu 177 dotatate injection 7.4 GBq (200 mCi) administered every 8 to 16 weeks concurrently with the recommended amino acid solution and with long-acting octreotide (30 mg administered by intramuscular injection within 24 hours of each lutetium Lu 177 dotatate injection dose) (N = 111), or high-dose octreotide (defined as long-acting octreotide 60 mg by intramuscular injection every 4 weeks) (N = 112) [see Clinical Studies ( 14.1 ) ]. Among patients receiving lutetium Lu 177 dotatate injection with octreotide, 79% received a cumulative dose > 22.2 GBq (> 600 mCi) and 76% of patients received all four planned doses. Six percent (6%) of patients required a dose reduction and 13% of patients discontinued lutetium Lu 177 dotatate injection. Five patients discontinued lutetium Lu 177 dotatate injection for renal-related events and 4 discontinued for hematological toxicities. Table 4 and Table 5 summarize the incidence of adverse reactions and laboratory abnormalities, respectively. The most common Grade 3-4 adverse reactions occurring with a greater frequency among patients receiving lutetium Lu 177 dotatate injection with octreotide compared to patients receiving high-dose octreotide include: lymphopenia (44%), increased gamma-glutamyltransferase (GGT) (20%), vomiting (7%), nausea and increased aspartate aminotransferase (AST) (5% each), and increased alanine aminotransferase (ALT), hyperglycemia and hypokalemia (4% each). Table 4. Adverse Reactions Occurring at Higher Incidence in Patients Receiving Lutetium Lu 177 Dotatate Injection with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of ≥ 5% All Grades or ≥ 2% Grades 3-4) a Adverse reaction a Lutetium Lu 177 Dotatate Injection with Long-acting Octreotide (30 mg) (N = 111) Long-acting Octreotide (60 mg) (N = 112) All Grades % Grades 3-4 % All Grades % Grades 3-4 % Gastrointestinal disorders Nausea 65 5 12 2 Vomiting 53 7 10 0 Abdominal pain 26 3 19 3 Diarrhea 26 3 18 1 Constipation 10 0 5 0 General disorders Fatigue 38 1 26 2 Peripheral edema 16 0 9 1 Pyrexia 8 0 3 0 Metabolism and nutrition disorders Decreased appetite 21 0 11 3 Nervous system disorders Headache 17 0 5 0 Dizziness 17 0 8 0 Dysgeusia 8 0 2 0 Vascular disorders Flushing 14 1 9 0 Hypertension 12 2 7 2 Musculoskeletal and connective tissue disorders Back pain 13 2 10 0 Pain in extremity 11 0 5 0 Myalgia 5 0 0 0 Neck pain 5 0 0 0 Renal and urinary disorders Renal failure b 13 3 4 1 Radiation-related urinary tract adverse reactions c 8 0 3 0 Psychiatric disorders Anxiety 12 1 5 0 Skin and subcutaneous tissue disorders Alopecia 12 0 2 0 Respiratory, thoracic and mediastinal disorders Cough 11 1 6 0 Cardiac disorders Atrial fibrillation 5 1 0 0 a National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays adverse reactions occurring at a higher incidence in lutetium Lu 177 dotatate injection-treated patients [between arm difference of ≥ 5% (all Grades) or ≥ 2% (Grades 3-4)]. b Includes the terms: Glomerular filtration rate decreased, acute kidney injury, acute prerenal failure, azotemia, renal disorder, renal failure, renal impairment. c Includes the terms: Dysuria, micturition urgency, nocturia, pollakiuria, renal colic, renal pain, urinary tract pain and urinary incontinence. Table 5. Laboratory Abnormalities Occurring at Higher Incidence in Patients Receiving Lutetium Lu 177 Dotatate Injection with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of ≥ 5% All Grades or ≥ 2% Grades 3-4) a,b Laboratory abnormality b Lutetium Lu 177 Dotatate Injection with Long-acting Octreotide (30 mg) (N = 111) Long-acting Octreotide (60 mg) (N = 112) All Grades % Grades 3-4 % All Grades % Grades 3-4 % Hematology Lymphopenia 90 44 39 5 Anemia 81 0 55 1 Leukopenia 55 2 20 0 Thrombocytopenia 53 1 17 0 Neutropenia 26 3 11 0 Renal/Metabolic Creatinine increased 85 1 73 0 Hyperglycemia 82 4 67 2 Hyperuricemia 34 6 30 6 Hypocalcemia 32 0 14 0 Hypokalemia 26 4 21 2 Hyperkalemia 19 0 11 0 Hypernatremia 17 0 7 0 Hypoglycemia 15 0 8 0 Hepatic GGT increased 66 20 67 16 Alkaline phosphatase increased 65 5 55 9 AST increased 50 5 35 0 ALT increased 43 4 34 0 Blood bilirubin increased 30 2 28 0 a Values are worst grade observed after randomization. b National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Only displays laboratory abnormalities occurring at a higher incidence in lutetium Lu 177 dotatate injection-treated patients [between arm difference of ≥ 5% (all Grades) or ≥ 2% (Grades 3-4)]. ERASMUS Safety data are available from 1214 patients in ERASMUS, an international, single-institution, single-arm, open-label trial of patients with somatostatin receptor-positive tumors (neuroendocrine and other primaries). Patients received lutetium Lu 177 dotatate injection 7.4 GBq (200 mCi) administered every 6 to 13 weeks with or without octreotide. Retrospective medical record review was conducted on a subset of 811 patients to document serious adverse reactions. Eighty-one (81%) percent of patients in the subset received a cumulative dose ≥ 22.2 GBq (≥ 600 mCi). With a median follow-up time of more than 4 years, the following rates of serious adverse reactions were reported: myelodysplastic syndrome (2%), acute leukemia (1%), renal failure (2%), hypotension (1%), cardiac failure (2%), myocardial infarction (1%), and neuroendocrine hormonal crisis (1%). Pediatric use information is approved for Advanced Accelerator Applications USA INC’s LUTATHERA (lutetium Lu 177 dotatate) injection for intravenous use. However, due to Advanced Accelerator Applications USA Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of lutetium Lu 177 dotatate injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders : hypersensitivity reactions, including angioedema

adverse reactions table

<table> <caption>Table 4. Adverse Reactions Occurring at Higher Incidence in Patients Receiving Lutetium Lu 177 Dotatate Injection with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of &#x2265; 5% All Grades or &#x2265; 2% Grades 3-4) <sup>a</sup> </caption> <col width="193"/> <col width="115"/> <col width="115"/> <col width="115"/> <col width="115"/> <tbody> <tr> <td align="center" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Adverse reaction <sup>a</sup> </content> </td> <td colspan="2" align="center" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Lutetium </content> <content styleCode="bold">Lu 177 </content> <content styleCode="bold">Dotatate Injection </content> <content styleCode="bold">with Long-acting Octreotide</content> <content styleCode="bold"> (30 mg) </content> <content styleCode="bold"> (N = 111) </content> </td> <td colspan="2" align="center" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Long-acting Octreotide</content> <content styleCode="bold"> (60 mg) </content> <content styleCode="bold"> (N = 112) </content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule"/> <td align="center" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td align="center" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Grades 3-4</content> <content styleCode="bold">%</content> </td> <td align="center" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td align="center" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Grades 3-4</content> <content styleCode="bold">%</content> </td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Gastrointestinal disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Nausea</td> <td styleCode="Lrule Rrule Toprule">65</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">12</td> <td styleCode="Lrule Rrule Toprule">2</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Vomiting</td> <td styleCode="Lrule Rrule Toprule">53</td> <td styleCode="Lrule Rrule Toprule">7</td> <td styleCode="Lrule Rrule Toprule">10</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Abdominal pain</td> <td styleCode="Lrule Rrule Toprule">26</td> <td styleCode="Lrule Rrule Toprule">3</td> <td styleCode="Lrule Rrule Toprule">19</td> <td styleCode="Lrule Rrule Toprule">3</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Diarrhea</td> <td styleCode="Lrule Rrule Toprule">26</td> <td styleCode="Lrule Rrule Toprule">3</td> <td styleCode="Lrule Rrule Toprule">18</td> <td styleCode="Lrule Rrule Toprule">1</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Constipation</td> <td styleCode="Lrule Rrule Toprule">10</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">General disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Fatigue</td> <td styleCode="Lrule Rrule Toprule">38</td> <td styleCode="Lrule Rrule Toprule">1</td> <td styleCode="Lrule Rrule Toprule">26</td> <td styleCode="Lrule Rrule Toprule">2</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Peripheral edema</td> <td styleCode="Lrule Rrule Toprule">16</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">9</td> <td styleCode="Lrule Rrule Toprule">1</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Pyrexia</td> <td styleCode="Lrule Rrule Toprule">8</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">3</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Metabolism and nutrition disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Decreased appetite</td> <td styleCode="Lrule Rrule Toprule">21</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">11</td> <td styleCode="Lrule Rrule Toprule">3</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Nervous system disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Headache</td> <td styleCode="Lrule Rrule Toprule">17</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Dizziness</td> <td styleCode="Lrule Rrule Toprule">17</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">8</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Dysgeusia</td> <td styleCode="Lrule Rrule Toprule">8</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">2</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Vascular disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Flushing</td> <td styleCode="Lrule Rrule Toprule">14</td> <td styleCode="Lrule Rrule Toprule">1</td> <td styleCode="Lrule Rrule Toprule">9</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Hypertension</td> <td styleCode="Lrule Rrule Toprule">12</td> <td styleCode="Lrule Rrule Toprule">2</td> <td styleCode="Lrule Rrule Toprule">7</td> <td styleCode="Lrule Rrule Toprule">2</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Musculoskeletal and connective tissue disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Back pain</td> <td styleCode="Lrule Rrule Toprule">13</td> <td styleCode="Lrule Rrule Toprule">2</td> <td styleCode="Lrule Rrule Toprule">10</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Pain in extremity</td> <td styleCode="Lrule Rrule Toprule">11</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Myalgia</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Neck pain</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Renal and urinary disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Renal failure <content styleCode="italics"> <sup>b</sup> </content> </td> <td styleCode="Lrule Rrule Toprule">13</td> <td styleCode="Lrule Rrule Toprule">3</td> <td styleCode="Lrule Rrule Toprule">4</td> <td styleCode="Lrule Rrule Toprule">1</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Radiation-related urinary tract adverse reactions <content styleCode="italics"> <sup>c</sup> </content> </td> <td styleCode="Lrule Rrule Toprule">8</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">3</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Psychiatric disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Anxiety</td> <td styleCode="Lrule Rrule Toprule">12</td> <td styleCode="Lrule Rrule Toprule">1</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Skin and subcutaneous tissue disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Alopecia</td> <td styleCode="Lrule Rrule Toprule">12</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">2</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Cough</td> <td styleCode="Lrule Rrule Toprule">11</td> <td styleCode="Lrule Rrule Toprule">1</td> <td styleCode="Lrule Rrule Toprule">6</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Cardiac disorders</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Atrial fibrillation</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">1</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> </tbody> </table>

adverse reactions table

<table> <caption>Table 5. Laboratory Abnormalities Occurring at Higher Incidence in Patients Receiving Lutetium Lu 177 Dotatate Injection with Long-Acting Octreotide Compared to High-Dose Long-Acting Octreotide (Between Arm Difference of &#x2265; 5% All Grades or &#x2265; 2% Grades 3-4) <sup>a,b</sup> </caption> <col width="222"/> <col width="108"/> <col width="108"/> <col width="108"/> <col width="108"/> <tbody> <tr> <td styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Laboratory abnormality</content> <content styleCode="bold"> <sup>b</sup> </content> </td> <td colspan="2" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Lutetium </content> <content styleCode="bold">Lu 177 </content> <content styleCode="bold">Dotatate Injection </content> <content styleCode="bold">with Long-acting Octreotide</content> <content styleCode="bold"> (30 mg) </content> <content styleCode="bold"> (N = 111) </content> </td> <td colspan="2" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Long-acting Octreotide</content> <content styleCode="bold"> (60 mg) </content> <content styleCode="bold"> (N = 112) </content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule"/> <td styleCode="Lrule Rrule Toprule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Grades 3-4</content> <content styleCode="bold">%</content> </td> <td styleCode="Lrule Rrule Toprule"> <content styleCode="bold">All Grades</content> <content styleCode="bold">%</content> </td> <td styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Grades 3-4</content> <content styleCode="bold">%</content> </td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Hematology</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Lymphopenia</td> <td styleCode="Lrule Rrule Toprule">90</td> <td styleCode="Lrule Rrule Toprule">44</td> <td styleCode="Lrule Rrule Toprule">39</td> <td styleCode="Lrule Rrule Toprule">5</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Anemia</td> <td styleCode="Lrule Rrule Toprule">81</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">55</td> <td styleCode="Lrule Rrule Toprule">1</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Leukopenia</td> <td styleCode="Lrule Rrule Toprule">55</td> <td styleCode="Lrule Rrule Toprule">2</td> <td styleCode="Lrule Rrule Toprule">20</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Thrombocytopenia</td> <td styleCode="Lrule Rrule Toprule">53</td> <td styleCode="Lrule Rrule Toprule">1</td> <td styleCode="Lrule Rrule Toprule">17</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Neutropenia</td> <td styleCode="Lrule Rrule Toprule">26</td> <td styleCode="Lrule Rrule Toprule">3</td> <td styleCode="Lrule Rrule Toprule">11</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Renal/Metabolic</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Creatinine increased</td> <td styleCode="Lrule Rrule Toprule">85</td> <td styleCode="Lrule Rrule Toprule">1</td> <td styleCode="Lrule Rrule Toprule">73</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Hyperglycemia</td> <td styleCode="Lrule Rrule Toprule">82</td> <td styleCode="Lrule Rrule Toprule">4</td> <td styleCode="Lrule Rrule Toprule">67</td> <td styleCode="Lrule Rrule Toprule">2</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Hyperuricemia</td> <td styleCode="Lrule Rrule Toprule">34</td> <td styleCode="Lrule Rrule Toprule">6</td> <td styleCode="Lrule Rrule Toprule">30</td> <td styleCode="Lrule Rrule Toprule">6</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Hypocalcemia</td> <td styleCode="Lrule Rrule Toprule">32</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">14</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Hypokalemia</td> <td styleCode="Lrule Rrule Toprule">26</td> <td styleCode="Lrule Rrule Toprule">4</td> <td styleCode="Lrule Rrule Toprule">21</td> <td styleCode="Lrule Rrule Toprule">2</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Hyperkalemia</td> <td styleCode="Lrule Rrule Toprule">19</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">11</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Hypernatremia</td> <td styleCode="Lrule Rrule Toprule">17</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">7</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Hypoglycemia</td> <td styleCode="Lrule Rrule Toprule">15</td> <td styleCode="Lrule Rrule Toprule">0</td> <td styleCode="Lrule Rrule Toprule">8</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td colspan="5" styleCode="Lrule Rrule Toprule"> <content styleCode="bold">Hepatic</content> </td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">GGT increased</td> <td styleCode="Lrule Rrule Toprule">66</td> <td styleCode="Lrule Rrule Toprule">20</td> <td styleCode="Lrule Rrule Toprule">67</td> <td styleCode="Lrule Rrule Toprule">16</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Alkaline phosphatase increased</td> <td styleCode="Lrule Rrule Toprule">65</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">55</td> <td styleCode="Lrule Rrule Toprule">9</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">AST increased</td> <td styleCode="Lrule Rrule Toprule">50</td> <td styleCode="Lrule Rrule Toprule">5</td> <td styleCode="Lrule Rrule Toprule">35</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">ALT increased</td> <td styleCode="Lrule Rrule Toprule">43</td> <td styleCode="Lrule Rrule Toprule">4</td> <td styleCode="Lrule Rrule Toprule">34</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> <tr> <td styleCode="Lrule Rrule Toprule">Blood bilirubin increased</td> <td styleCode="Lrule Rrule Toprule">30</td> <td styleCode="Lrule Rrule Toprule">2</td> <td styleCode="Lrule Rrule Toprule">28</td> <td styleCode="Lrule Rrule Toprule">0</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.